Natixis Sells 353 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Natixis lowered its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 6.7% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,884 shares of the company’s stock after selling 353 shares during the quarter. Natixis’ holdings in IDEXX Laboratories were worth $2,019,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the stock. Hurley Capital LLC bought a new stake in IDEXX Laboratories during the 4th quarter worth approximately $29,000. Rialto Wealth Management LLC purchased a new stake in shares of IDEXX Laboratories in the fourth quarter worth $30,000. Retirement Wealth Solutions LLC bought a new stake in shares of IDEXX Laboratories during the 4th quarter valued at $31,000. Kestra Investment Management LLC purchased a new position in shares of IDEXX Laboratories during the 4th quarter valued at $38,000. Finally, Crews Bank & Trust bought a new position in IDEXX Laboratories in the 4th quarter worth $41,000. 87.84% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have recently commented on IDXX. StockNews.com downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, April 12th. Stifel Nicolaus dropped their price target on IDEXX Laboratories from $450.00 to $420.00 and set a “hold” rating for the company in a research note on Monday, April 14th. Morgan Stanley reduced their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 29th. Barclays boosted their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a report on Tuesday, February 4th. Finally, Bank of America raised their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a research note on Tuesday, February 4th. Four investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and an average price target of $523.75.

Insiders Place Their Bets

In other IDEXX Laboratories news, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the transaction, the executive vice president now directly owns 8,176 shares of the company’s stock, valued at $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director M Anne Szostak sold 3,000 shares of the business’s stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the transaction, the director now owns 3,061 shares in the company, valued at $1,426,242.34. This trade represents a 49.50 % decrease in their position. The disclosure for this sale can be found here. 0.98% of the stock is currently owned by insiders.

IDEXX Laboratories Stock Performance

IDEXX Laboratories stock opened at $421.59 on Wednesday. The company’s 50-day moving average price is $420.59 and its 200-day moving average price is $429.92. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The company has a market cap of $34.17 billion, a PE ratio of 39.51, a price-to-earnings-growth ratio of 3.41 and a beta of 1.50. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $548.88.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.